ACS Medicinal Chemistry Letters

Letter


Design of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors

Md. Jashim Uddin, Anna V. Elleman, Kebreab Ghebreselasie, Cristina K. Daniel, Brenda C. Crews, Kellie D. Nance, Tamanna Huda, and Lawrence J. Marnett*

A. B. Hancock, Jr., Memorial Laboratory for Cancer Research, Department of Biochemistry, Chemistry and Pharmacology, Vanderbilt Institute of Chemical Biology, Center for Molecular Toxicology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States

(5) Supporting Information

ABSTRACT: We report the design and synthesis of fluorine-containing cyclooxygenase-1 (COX-1)-selective inhibitors to serve as prototypes for the development of a COX-1-targeted imaging agent. Deletion of the SO_2CH_3 group of rofecoxib switches the compound from a COX-2- to a COX-1-selective inhibitor, providing a 3,4-diarylfuran-2(5*H*)-one scaffold for structure–activity relationship studies of COX-1 inhibition. A wide range of fluorine-containing 3,4-diarylfuran-2(5*H*)-ones were designed, synthesized, and tested for their ability to selectively inhibit COX-1 in purified protein and human cancer cell assays. Compounds containing a fluoro-



substituent on the C-3 phenyl ring and a methoxy-substituent on the C-4 phenyl ring of the 3,4-diarylfuran-2(5*H*)-one scaffold were the best COX-1-selective agents of those evaluated, exhibiting IC_{50} s in the submicromolar range. These compounds provide the foundation for development of an agent to facilitate radiologic imaging of ovarian cancer expressing elevated levels of COX-1. **KEYWORDS:** *Cyclooxygenase-1 (COX-1), rofecoxib, furanone, structure–activity relationship, imaging*

he cyclooxygenase enzymes (COX-1 and COX-2), which catalyze the first two steps in the biosynthesis of prostaglandins from arachidonic acid, are the primary targets of the nonsteroidal anti-inflammatory drugs, such as indomethacin, ibuprofen, and naproxen. The inducible isoform, COX-2, is strongly expressed in response to inflammatory and mitogenic stimuli, leading to the widely accepted belief that this enzyme plays an important role in inflammation and carcinogenesis.¹ However, growing evidence suggests that the constitutively expressed COX-1 also contributes to some disease processes, including neuroinflammation, thrombosis, and some cancers.²⁻⁶ Of the cancers reported to overexpress COX-1, the strongest case has been made for epithelial ovarian cancer. Indeed, recent evidence suggests that COX-1 contributes to the pathophysiology of ovarian cancer and that COX-1 inhibition may have both preventive and therapeutic benefits in this disease.⁷⁻¹¹

We have shown that COX-2-selective inhibitors bearing fluorescent, ¹⁸F, or ¹²³I tags can be used in conjunction with optical, positron emission tomography (PET), or single-photon emission computerized tomography imaging modalities, respectively, to visualize COX-2 expressed in tumors and inflammatory sites in vivo.^{12–16} These findings led us to hypothesize that COX-1 could serve as an imaging target to detect ovarian cancer, a disease for which better diagnostic modalities are sorely needed. To that end, selective uptake of an [¹⁸F]-labeled analogue of the COX-1-selective inhibitor P6 (3-(5-chlorofuran-2-yl)-5-(fluoromethyl)-4-phenylisoxazole) by COX-1-expressing ovarian carcinoma xenografts was recently

reported.¹⁷ These studies provided proof-of-concept for COX-1 targeting in ovarian cancer; however, it has been difficult to achieve adequate potency, selectivity, and pharmacokinetic properties for in vivo imaging using the P6 scaffold.¹⁸ To date, only a very few COX-1-selective inhibitors have been reported. Although a few have been built on benzamide or sulindac sulfide scaffolds,^{19–21} most have employed a pyrazole-, thiazole-, triazole-, or isoxazole-containing diaryl heterocycle scaffold similar to that of the COX-2-selective inhibitors, celecoxib, rofecoxib, and valdecoxib (Figure 1).^{22–28} Here, we report that the 3,4-diphenylfuran-2(5H)-one obtained from desulfurization of rofecoxib exhibits a weak COX-1-selective inhibitory activity. Furthermore, we describe the structure—activity relationships obtained from the modification of that




Figure 1. Nitrogen-containing diaryl heterocyclic class of COX-1-selective inhibitors.


Received:August 25, 2014Accepted:October 12, 2014Published:October 12, 2014

ACS Publications © 2014 American Chemical Society

scaffold to obtain potent and selective fluorine-containing COX-1 inhibitors suitable for use as a prototype for the development of a PET imaging agent.

The key determinant of the COX-2-selectivity of the diaryl heterocycle-based COX-2 inhibitors is the presence of a sulfonamide or a methylsulfone on one of the aromatic rings. This sulfur-containing functional group inserts into a sidepocket in the cyclooxygenase active site that is only accessible in COX-2. Interestingly, the COX-1-selective inhibitor SC-560 was derived from celecoxib via replacement of the sulfonamide group with a methoxy group.²⁹ Similarly, deletion of the sulfonylmethyl group of rofecoxib affords 3,4-diphenylfuran-2(5H)-one (1), which exhibits a weak COX-1 inhibitory activity, suggesting that it could serve as a scaffold for the discovery of novel selective COX-1 inhibitors. We employed an efficient one-pot parallel synthetic method for the synthesis of fluorinated 3,4-diarylfuran-2(5H)-one derivatives involving condensation of a group of substituted-phenacyl bromides with substituted-phenylacetic acids followed by intramolecular cyclization of the acetate intermediate using 1,8diazabicyclo[5.4.0]undec-7-ene (Scheme 1).³⁰ The IC₅₀ values

Scheme 1. One-Pot Synthesis of Fluorine-Containing 3,4-Diarylfuran-2(5H)-one 1–40 or 3-Pyridyl-4-arylfuran-2(5H)-one derivatives 41–48^{*a*}



^{*a*}Reagents and conditions: (a) acetonitrile, triethylamine, room temperature, 20 min; (b) 1,8-diazabicyclo[5.4.0]undec-7-ene, room temperature, 20 min.

for inhibition of purified murine COX-2 or ovine COX-1 by test compounds were determined by a thin layer chromatog-raphy (TLC)-based assay that measures the conversion of $[1^{-14}C]$ -arachidonic acid to radiolabeled prostaglandins.¹³

The first series of compounds that were synthesized by this approach possessed halogen substituents at the 2-, 3-, or 4-positions of the C-4 phenyl ring of 3,4-diphenyl-2(5*H*)-furanone. Compounds possessing a fluoro substituent at these positions (compounds 2-4) exhibited no COX inhibitory activity. Attachment of methyl, hydroxymethyl, methoxy, dimethylamino, bromo, or chloro substituents to the C-3 phenyl ring of these fluorinated derivatives similarly produced inactive compounds (compounds 5-16, Table 1). Thus, we concluded that compounds bearing a fluoro-substituent on the C-4 phenyl ring of 3,4-diphenyl-2(5*H*)-furanone are inactive as COX inhibitors.

The second series of compounds possessed halogencontaining substituents at the 2-, 3-, or 4-positions of the C-3 phenyl ring and a range of substituents in the para-position of the C-4 phenyl ring of the scaffold (Table 2). Of these, the most potent selective COX-1 inhibitors possessed a 4-methoxy group in the C-4 phenyl ring. Compounds containing this substituent along with a 3-fluoro (27), 4-fluoro (28), 4-iodo Table 1. In Vitro Biochemical Properties of 3-Aryl-4-(2-, 3-,or 4-fluorophenyl)-furan-2(5H)-one Derivatives

				1-16	
	no.	\mathbb{R}^1	R ²	oCOX-1 IC ₅₀ $(\mu M)^a$	mCOX-2 IC ₅₀ $(\mu M)^a$
	1	Н	Н	5.90	>25
	2	2-F	Н	>25	>25
	3	3-F	Н	>25	>25
	4	4-F	Н	>25	>25
	5	2-F	4-CH ₃	>25	>25
	6	3-F	4-CH ₃	>25	>25
	7	4-F	4-CH ₃	>25	>25
	8	2-F	4-CH ₂ OH	>25	>25
	9	4-F	4-CH ₂ OH	>25	>25
	10	4-F	4-OH	>25	>25
	11	2-F	$4-N(CH_3)_2$	>25	>25
	12	4-F	$4 - N(CH_3)_2$	>25	>25
	13	2-F	4-Br	>25	>25
	14	4-F	4-Br	>25	>25
	15	2-F	4-Cl	>25	>25
	16	4-F	4-Cl	>25	>25

 $^{a}IC_{50}$ values were determined by incubating several concentrations of inhibitors or DMSO vehicle with purified murine COX-2 (63 nM) or ovine COX-1 (22.5 nM) for 20 min, followed by treatment with $[1^{-14}C]$ -arachidonic acid (50 μ M) at 37 °C for 30 s. Assays were run in duplicate.

(30), or 3-chloro-2-fluoro (32) group in the C-3 phenyl ring all exhibited submicromolar IC₅₀s against COX-1, while residual activity of COX-2 in the presence of 25 μ M of the compounds was higher than 50% (IC₅₀ > 25 μ M). A *p*-bromo-substituted compound (29) was also a potent COX-1 inhibitor, but demonstrated some activity against COX-2, while 3- and 4trifluoromethyl-substituted compounds (39 and 40) exhibited weak COX-1-selective activity, and unsubstituted (25), 2fluoro-substituted (26), and 4-fluorophenoxy-substituted (31) compounds were inactive. Of four compounds bearing no substituent on the C-4 phenyl ring (17-20), only one, with a 4-fluoro substituent in the C-3 phenyl ring, demonstrated weak COX-1 inhibitory activity. Two out of five compounds (21-24) bearing a 4-methyl group in the C-4 ring exhibited selective COX-1 inhibitory activity with IC₅₀s in the low micromolar range. These compounds contained 2-fluoro (21) and 4-fluoro (23) substituents in the C-3 phenyl ring. Compounds bearing a 3-fluoro substituent in the C-3 phenyl ring with 4-cyano (35), 4-ethyl (37), and 4-hydroxyl (38) groups in the C-4 phenyl ring were selective COX-1 inhibitors with a range of IC₅₀s from 0.4 to 10 μ M. A single compound bearing a 4-fluoro group in the C-4 phenyl ring and a 4-thiomethyl group in the C-3 phenyl ring (36) was inactive.

The third series of compounds possessed a substituted phenyl ring at the C-4 position and a substituted-4-pyridyl ring at the C-3 position on the furanone core. Compounds **41** through **48** were synthesized from the reaction of methyl-, methoxy-, chloro-, or cyano-substituted phenacyl bromides and 2-chloro- or 2-fluoro-4-pyridylacetic acids, followed by a cyclization reaction. These pyridyl analogues showed COX-1-selective inhibition with very low levels of potency (Scheme 1 and Table 3).

Table 2. In Vitro Biochemical Properties of 3-(2-, 3-, or 4-Fluorophenyl)-4-arylfuran-2(5H)-one Derivatives



no.	\mathbb{R}^1	R ²	oCOX-1 IC ₅₀ $(\mu M)^a$	${ m mCOX-2\ IC_{50}} {(\mu{ m M})^a}$
17	Н	2-F	>25	>25
18	Н	3-F	>25	>25
19	Н	4-F	6	>25
20	Н	4-OPhF	>25	>25
21	CH ₃	2-F	1.00	>25
22	CH ₃	3-F	>25	>25
23	CH ₃	4-F	0.95	>25
24	CH ₃	4-OPhF	>25	>25
25	OCH ₃	Н	>25	>25
26	OCH ₃	2-F	>25	>25
27	OCH ₃	3-F	0.36	>25
28	OCH ₃	4-F	0.48	>25
29	OCH ₃	4-Br	0.12	0.45
30	OCH ₃	4-I	0.09	>25
31	OCH ₃	4-OPhF	>25	>25
32	OCH ₃	2-F, 3-Cl	0.30	>25
33	CF ₃	3-F	>25	>25
34	OCF ₃	3-F	>25	>25
35	CN	3-F	0.47	>25
36	SCH ₃	4-F	>25	>25
37	CH_2CH_3	3-F	9.75	>25
38	OH	3-F	1.75	>25
39	OCH ₃	3-CF ₃	8.80	>25
40	OCH ₃	4-CF ₃	1.00	>25
R	SO_2CH_3	Н	>25	0.06

 $^{a}IC_{50}$ values were determined by incubating several concentrations of inhibitors or DMSO vehicle with purified murine COX-2 (63 nM) or ovine COX-1 (22.5 nM) for 20 min followed by treatment with [1-¹⁴C]-AA (50 μ M) at 37 °C for 30 s. Assays were run in duplicate. Compound **R** is rofecoxib.

Table 3. Biochemical Properties of 3-(2-Chloro or 2-Fluoropyridin-4-yl)-4-arylfuran-2(5H)-one Derivatives

41-48					
no.	\mathbb{R}^1	\mathbb{R}^2	oCOX-1 IC ₅₀ $(\mu M)^a$	mCOX-2 IC ₅₀ $(\mu M)^a$	
41	OCH ₃	F	4.60	>25	
42	OCH ₃	Cl	4.40	>25	
43	Cl	Cl	>25	>25	
44	Cl	F	15.70	>25	
45	CH ₃	Cl	5.00	>25	
46	CH ₃	F	>25	>25	
47	CN	F	4.40	>25	
48	CN	Cl	3.00	>25	

 ${}^{a}IC_{50}$ values were determined by incubating several concentrations of inhibitors or DMSO vehicle with purified murine COX-2 (63 nM) or ovine COX-1 (22.5 nM) for 20 min followed by treatment with [1- ${}^{14}C$]-AA (50 μ M) at 37 °C for 30 s. Assays were run in duplicate.

The ability of the promising fluorine-containing furanone derivatives to inhibit COX-1 and COX-2 in intact cells was evaluated using COX-1-expressing human ovarian cancer cells (OVCAR3) and COX-2-expressing human head and neck squamous cell carcinoma cells (1483 HNSCC).^{13,17} Selected compounds were incubated with these cells in the presence of [1-¹⁴C]-arachidonic acid, and COX-mediated formation of prostaglandin products was monitored by a TLC assay.^{13,17} Compounds **19**, **23**, **27**, and **28** inhibited COX-1 in OVCAR3 cells but not COX-2 in 1483 HNSCC cells (Table 4). Although

Table 4. In Vitro Inhibition of COX-1 in OVCAR3 and COX-2 in 1483 HNSCC Cell Line Assay Data of Promising Compounds

no.	OVCAR3 COX-1 IC ₅₀ $(\mu M)^a$	1483 HNSCC COX-2 IC ₅₀ $(\mu M)^a$		
19	2.80	>5		
23	0.78	>5		
27	0.18	>5		
28	0.36	>5		
30	>4	>5		
$^{a}IC_{50}$	values were determined	as described previously ^{13,17} for		

OVCAR3 or 1483 HNSCC cells.

compound **30** inhibited COX-1 in the purified protein assay, it did not inhibit COX-1 in OVCAR3 cells. The remaining fluorocompounds in Table 2 that exhibit low to moderate COX-1 inhibitory potency and selectivity in the purified COX enzyme assay were not evaluated in the OVCAR3 or 1483 HNSCC cell line assays.

Compound **27** was the most potent of those tested against COX-1 in OVCAR3 cells. We further characterized this compound to determine whether its inhibitory potency is time-dependent. In the standard TLC assay, which includes a 20 min preincubation, **27** exhibited an IC₅₀ of 0.36 μ M. Elimination of the preincubation resulted in only a small change in potency (IC₅₀ of 1.25 μ M). Thus, **27** may be an example of a rapid reversible inhibitor of COX-1. We also evaluated the effect of plasma proteins on inhibitor potency in the OVCAR3 cell assay, demonstrating a mild loss of potency when cells were treated with **27** in the presence of 10% FBS (IC₅₀ of 0.87 μ M) as compared to its potency in the absence of serum (IC₅₀ of 0.18 μ M).

In conclusion, we describe the SAR of a series of COX-1selective small molecules, which indicates that the regiochemical disposition of alkyl, thioalkyl, alkoxy, phenoxy, trifluoromethyl, halo, or other substituents on the 3,4-diphenylfuran-2(5H)-one core controls COX inhibitory activity, selectivity, and potency. In general, 4-methoxy substitution on the C-4 phenyl ring combined with 3- and 4-substitution with fluorinecontaining substituents in the C-3 phenyl ring was the most productive approach to potent and selective COX-1 inhibitors that may serve as prototypes for PET imaging agents. Further work will be required to develop the radiochemistry to incorporate an [¹⁸F] label and evaluate the compounds as in vivo imaging agents.

ASSOCIATED CONTENT

S Supporting Information

Full synthetic procedures and analytical and spectral characterization data of the synthesized compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

ACS Medicinal Chemistry Letters

AUTHOR INFORMATION

Corresponding Author

*Phone: 615-343-7329. Fax: 615-343-7534. E-mail: larry. marnett@vanderbilt.edu.

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Funding

This study is supported by research grants from the National Institutes of Health (CA89450, CA136465, and S10 RR019022).

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

Spectroscopic analysis of all new molecules was conducted in the Small Molecule NMR Facility and Mass Spectrometry Research Center at the Vanderbilt Institute of Chemical Biology.

ABBREVIATIONS

COX, cyclooxygenase; PET, positron emission tomography; TLC, thin layer chromatography

REFERENCES

(1) Smith, W. L.; DeWitt, D. L.; Garavito, R. M. Cyclooxygenases: structural, cellular, and molecular biology. *Annu. Rev. Biochem.* 2000, 69, 145–182.

(2) Vanhoutte, P. M. COX-1 and vascular disease. *Clin. Pharmacol. Ther.* **2009**, *86*, 212–215.

(3) Choi, S. H.; Aid, S.; Bosetti, F. The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. *Trends Pharmacol. Sci.* **2009**, *30*, 174–181.

(4) Erovic, B. M.; Woegerbauer, M.; Pammer, J.; Selzer, E.; Grasl, M.; Thurnher, D. Strong evidence for up-regulation of cyclooxygenase-1 in head and neck cancer. *Eur. J. Clin. Invest.* **2008**, 38, 61–66.

(5) Hwang, D.; Scollard, D.; Byrne, J.; Levine, E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. *J. Natl. Cancer Inst.* **1998**, *90*, 455–460.

(6) Kirschenbaum, A.; Klausner, A. P.; Lee, R.; Unger, P.; Yao, S.; Liu, X. H.; Levine, A. C. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. *Urology* **2000**, *56*, 671–676.

(7) Cho, M.; Kabir, S. M.; Dong, Y.; Lee, E.; Rice, V. M.; Khabele, D.; Son, D. S. Aspirin blocks EGF-stimulated cell viability in a COX-1 dependent manner in ovarian cancer cells. *J. Cancer* **2013**, *4*, 671–678.

(8) Daikoku, T.; Tranguch, S.; Chakrabarty, A.; Wang, D.; Khabele, D.; Orsulic, S.; Morrow, J. D.; Dubois, R. N.; Dey, S. K. Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. *Cancer Res.* **2007**, *67*, 5285–5292.

(9) Dore, M.; Cote, L. C.; Mitchell, A.; Sirois, J. Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas. J. Histochem. Cytochem. **1998**, *46*, 77–84.

(10) Gupta, R. A.; Tejada, L. V.; Tong, B. J.; Das, S. K.; Morrow, J. D.; Dey, S. K.; DuBois, R. N. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. *Cancer Res.* **2003**, *63*, 906–911.

(11) Lee, C. Y.; Chen, K. W.; Sheu, F. S.; Tsang, A.; Chao, K. C.; Ng, H. T. Studies of a tumor-associated antigen, COX-1, recognized by a monoclonal antibody. *Cancer Immunol. Immunother.* **1992**, *35*, 19–26. (12) Cekanova, M.; Uddin, M. J.; Bartges, J. W.; Callens, A.; Legendre, A. M.; Rathore, K.; Wright, L.; Carter, A.; Marnett, L. J. Molecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivo. *Cancer Prev. Res.* **2013**, *6*, 466–476. (13) Uddin, M. J.; Crews, B. C.; Blobaum, A. L.; Kingsley, P. J.; Gorden, D. L.; McIntyre, J. O.; Matrisian, L. M.; Subbaramaiah, K.; Dannenberg, A. J.; Piston, D. W.; Marnett, L. J. Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. *Cancer Res.* **2010**, *70*, 3618–3627.

(14) Uddin, M. J.; Crews, B. C.; Ghebreselasie, K.; Huda, I.; Kingsley, P. J.; Ansari, M. S.; Tantawy, M. N.; Reese, J.; Marnett, L. J. Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer. *Cancer Prev. Res.* **2011**, *4*, 1536–1545.

(15) Uddin, M. J.; Crews, B. C.; Ghebreselasie, K.; Marnett, L. J. Design, synthesis, and structure-activity relationship studies of fluorescent inhibitors of cycloxygenase-2 as targeted optical imaging agents. *Bioconjugate Chem.* **2013**, *24*, 712–723.

(16) Uddin, M. J.; Crews, B. C.; Ghebreselasie, K.; Tantawy, M. N.; Marnett, L. J. [I]-Celecoxib analogues as SPECT tracers of cyclooxygenase-2 in inflammation. *ACS Med. Chem. Lett.* **2011**, *2*, 160–164.

(17) Perrone, M. G.; Malerba, P.; Uddin, M. J.; Vitale, P.; Panella, A.; Crews, B. C.; Daniel, C. K.; Ghebreselasie, K.; Nickels, M.; Tantawy, M. N.; Manning, H. C.; Marnett, L. J.; Scilimati, A. PET radiotracer [(1)(8)F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation. *Eur. J. Med. Chem.* **2014**, *80*, 562–568.

(18) Teng, X. W.; Abu-Mellal, A. K.; Davies, N. M. Formulation dependent pharmacokinetics, bioavailability and renal toxicity of a selective cyclooxygenase-1 inhibitor SC-560 in the rat. *J. Pharm. Pharm. Sci.* **2003**, *6*, 205–210.

(19) Fukai, R.; Zheng, X.; Motoshima, K.; Tai, A.; Yazama, F.; Kakuta, H. Design and synthesis of novel cyclooxygenase-1 inhibitors as analgesics: 5-amino-2-ethoxy-N-(substituted-phenyl)benzamides. *ChemMedChem* **2011**, *6*, 550–560.

(20) Kakuta, H.; Zheng, X.; Oda, H.; Harada, S.; Sugimoto, Y.; Sasaki, K.; Tai, A. Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor. *J. Med. Chem.* **2008**, *51*, 2400–2411.

(21) Liedtke, A. J.; Crews, B. C.; Daniel, C. M.; Blobaum, A. L.; Kingsley, P. J.; Ghebreselasie, K.; Marnett, L. J. Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold. *J. Med. Chem.* **2012**, 55, 2287–2300.

(22) Calvello, R.; Panaro, M. A.; Carbone, M. L.; Cianciulli, A.; Perrone, M. G.; Vitale, P.; Malerba, P.; Scilimati, A. Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPSstimulated N13 microglial cells. *Pharmacol. Res.* **2012**, *65*, 137–148.

(23) Di Nunno, L.; Vitale, P.; Scilimati, A.; Tacconelli, S.; Patrignani, P. Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. *J. Med. Chem.* **2004**, *47*, 4881–4890.

(24) Imanishi, J.; Morita, Y.; Yoshimi, E.; Kuroda, K.; Masunaga, T.; Yamagami, K.; Kuno, M.; Hamachi, E.; Aoki, S.; Takahashi, F.; Nakamura, K.; Miyata, S.; Ohkubo, Y.; Mutoh, S. Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor. *Biochem. Pharmacol.* **2011**, *82*, 746–754.

(25) Kusuhara, H.; Fukunari, A.; Matsuyuki, H.; Okumoto, T. Principal involvement of cyclooxygenase-1-derived prostaglandins in the c-fos expression of the rat hind brain following visceral stimulation with acetic acid. *Brain Res. Mol. Brain Res.* **1997**, *52*, 151–156.

(26) Ochi, T.; Motoyama, Y.; Goto, T. The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models. *Eur. J. Pharmacol.* **2000**, *391*, 49–54.

(27) Ono, N.; Yamamoto, N.; Sunami, A.; Yamasaki, Y.; Miyake, H. Pharmacological profile of mofezolac, a new non-steroidal analgesic anti-inflammatory drug. *Nihon Yakurigaku Zasshi* **1990**, *95*, 63–81.

(28) Smith, C. J.; Zhang, Y.; Koboldt, C. M.; Muhammad, J.; Zweifel, B. S.; Shaffer, A.; Talley, J. J.; Masferrer, J. L.; Seibert, K.; Isakson, P. C. Pharmacological analysis of cyclooxygenase-1 in inflammation. *Proc. Natl. Acad. Sci. U.S.A.* **1998**, *95*, 13313–13318.

(29) Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J. Med. Chem. **1997**, 40, 1347–1365.

(30) Yamakawa, N.; Suzuki, K.; Yamashita, Y.; Katsu, T.; Hanaya, K.; Shoji, M.; Sugai, T.; Mizushima, T. Structure-activity relationship of celecoxib and rofecoxib for the membrane permeabilizing activity. *Bioorg. Med. Chem.* **2014**, *22*, 2529–2534.